Last updated: 2026-09-16 10:32:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
NewcelX Ltd. (NCEL) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $3,29, with a market capitalisation of $18,95M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,83 to $7,64. This page covers its latest market performance, valuation, price trends and company information.
$18,95M | |
$3,29 | |
$7,64 | |
$1,83 | |
$3,32 | |
-- | |
18,71K | |
-- | |
$7,64 | |
$1,83 | |
-- | |
-- |
NewcelX Ltd. (NCEL) is trading at $3,29 in pre-market trading as of 2026-09-16 08:32:00, down 1,05% ($0,03) from the previous close of $3,32
Pre-market trading shows how investors are pricing NCEL before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, NewcelX Ltd. (NCEL) moved from $3,35 to $3,29, representing a decline of 1,94% ($0,06).
The stock traded between $3,16 and $3,50 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 4,03 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 25,0%
NCEL is currently trading at $3,29, placing it 25,0% of the way from its 52-week low of $1,83 to its 52-week high of $7,64. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of NewcelX Ltd. (NCEL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.